Mesothelioma Treatment: Are We on Target? A Review

Overview

Journal J Adv Res

Specialties General Medicine
Science

Date 2015 Aug 11

PMID 26257929

Citations 15

Authors

Birgitta I Hiddinga

Christian Rolfo

Jan P van Meerbeeck

Affiliations

Soon will be listed here.

Abstract

Targeted treatment is a therapy directed at a specific molecular target close to a hallmark of cancer. The target should be measurable with a biomarker and measurement of the target should correlate with clinical outcome when targeted treatment is administered. Current clinical guidelines do not recommend targeted or biological therapy in MPM. However, since these recommendations came out, new agents have been investigated in MPM. This review updates the use of targeted and biological treatment in patients with mesothelioma.

Citing Articles

Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6.

Cioce M, Gatti V, Napolitano F, Giorgiano N, Marra A, Portella G Int J Mol Sci. 2024; 25(10).

PMID: 38791392 PMC: 11121414. DOI: 10.3390/ijms25105355.

The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach.

Forte I, Indovina P, Montagnaro S, Costa A, Iannuzzi C, Capone F Viruses. 2021; 13(12).

PMID: 34960727 PMC: 8703924. DOI: 10.3390/v13122458.

Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting .

Pinelli S, Alinovi R, Poli D, Corradi M, Pelosi G, Tiseo M Int J Mol Med. 2021; 47(6).

PMID: 33955505 PMC: 8083808. DOI: 10.3892/ijmm.2021.4950.

Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions.

Karunakaran K, Yanamala N, Boyce G, Becich M, Ganapathiraju M Cancers (Basel). 2021; 13(7).

PMID: 33916178 PMC: 8037232. DOI: 10.3390/cancers13071660.

Cytogenomic characterization of three murine malignant mesothelioma tumor cell lines.

Wahlbuhl E, Liehr T, Rincic M, Azawi S Mol Cytogenet. 2020; 13:43.

PMID: 32944078 PMC: 7488062. DOI: 10.1186/s13039-020-00511-4.

References

Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P . Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2009; 35(3):479-95. DOI: 10.1183/09031936.00063109. View

Sekido Y . Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2009; 101(1):1-6. PMC: 11159396. DOI: 10.1111/j.1349-7006.2009.01336.x. View

Papa S, Popat S, Shah R, Prevost A, Lal R, McLennan B . Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013; 8(6):783-7. DOI: 10.1097/JTO.0b013e31828c2b26. View

Ceresoli G, Zucali P, Mencoboni M, Botta M, Grossi F, Cortinovis D . Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013; 109(3):552-8. PMC: 3738125. DOI: 10.1038/bjc.2013.368. View

Szlosarek P, Steele J, Nolan L, Gilligan D, Taylor P, Spicer J . Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncol. 2016; 3(1):58-66. DOI: 10.1001/jamaoncol.2016.3049. View

Zauderer M, Bott M, McMillan R, Sima C, Rusch V, Krug L . Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol. 2013; 8(11):1430-3. PMC: 4343301. DOI: 10.1097/JTO.0b013e31829e7ef9. View

Stahel R, Weder W, Lievens Y, Felip E . Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v126-8. DOI: 10.1093/annonc/mdq173. View

Currie A, Prosser A, McDonnell A, Cleaver A, Robinson B, Freeman G . Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol. 2009; 183(12):7898-908. DOI: 10.4049/jimmunol.0901060. View

Hassan R, Kindler H, Jahan T, Bazhenova L, Reck M, Thomas A . Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014; 20(23):5927-36. PMC: 4252585. DOI: 10.1158/1078-0432.CCR-14-0804. View

10.

Poulikakos P, Xiao G, Gallagher R, Jablonski S, Jhanwar S, Testa J . Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006; 25(44):5960-8. DOI: 10.1038/sj.onc.1209587. View

11.

Jahan T, Gu L, Kratzke R, Dudek A, Otterson G, Wang X . Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2011; 76(3):393-6. PMC: 4778731. DOI: 10.1016/j.lungcan.2011.11.014. View

12.

Feng Y, Thiagarajan P, Ma P . MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 2012; 7(2):459-67. DOI: 10.1097/JTO.0b013e3182417e44. View

13.

Pirker R, Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R . Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373(9674):1525-31. DOI: 10.1016/S0140-6736(09)60569-9. View

14.

Mossman B, Shukla A, Heintz N, Verschraegen C, Thomas A, Hassan R . New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol. 2013; 182(4):1065-77. PMC: 3657618. DOI: 10.1016/j.ajpath.2012.12.028. View

15.

Garland L, Rankin C, Gandara D, Rivkin S, Scott K, Nagle R . Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007; 25(17):2406-13. DOI: 10.1200/JCO.2006.09.7634. View

16.

Delage B, Fennell D, Nicholson L, McNeish I, Lemoine N, Crook T . Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010; 126(12):2762-72. DOI: 10.1002/ijc.25202. View

17.

Jamal S, Cheriyan V, Muthu M, Munie S, Levi E, Ashour A . CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells. PLoS One. 2014; 9(3):e89146. PMC: 3943785. DOI: 10.1371/journal.pone.0089146. View

18.

Peto J, Decarli A, La Vecchia C, Levi F, Negri E . The European mesothelioma epidemic. Br J Cancer. 1999; 79(3-4):666-72. PMC: 2362439. DOI: 10.1038/sj.bjc.6690105. View

19.

Hassan R, Miller A, Sharon E, Thomas A, Reynolds J, Ling A . Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5(208):208ra147. PMC: 6369691. DOI: 10.1126/scitranslmed.3006941. View

20.

Mansfield A, Roden A, Peikert T, Sheinin Y, Harrington S, Krco C . B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014; 9(7):1036-1040. PMC: 4058651. DOI: 10.1097/JTO.0000000000000177. View